Cantex Pharmaceuticals
Clinical trials sponsored by Cantex Pharmaceuticals, explained in plain language.
-
New combo therapy targets aggressive brain cancer in early trial
Disease control OngoingThis study tests whether adding the drug azeliragon to standard radiation and chemotherapy (temozolomide) is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 18 participants will receive the combination to find the best dose and check for side…
Phase: PHASE1, PHASE2 • Sponsor: Cantex Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for aggressive brain cancer: drug combo shows promise
Disease control OngoingThis study tests a new drug, azeliragon, combined with radiation therapy for people with a specific type of glioblastoma, an aggressive brain cancer. The goal is to see if this combination is safe and can slow cancer growth. About 30 adults with newly diagnosed, unmethylated glio…
Phase: PHASE2 • Sponsor: Cantex Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:19 UTC